Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Ibnsina Pharma's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:ISPH vs MCK, COR, CAH: Buyback Yield % Comparison
For the Medical Distribution subindustry, Ibnsina Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ibnsina Pharma Buyback Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Ibnsina Pharma's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ibnsina Pharma (CAI:ISPH) has a Buyback Yield % of 0.00 as of Aug. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Ibnsina Pharma and its competitors. According to the industry distribution chart, Ibnsina Pharma ranks #999999 out of 37 companies in the Medical Distribution industry.
Is Ibnsina Pharma's Buyback Yield % too high?
Ibnsina Pharma's current Buyback Yield % is 0.00. Based on the distribution chart, Ibnsina Pharma ranks #999999 out of 37 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Ibnsina Pharma has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Buyback Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ibnsina Pharma ranks #999999 out of 37 companies for Buyback Yield %. This places Ibnsina Pharma in the lower half of its industry. The industry median Buyback Yield % is 0.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Distribution company?
The median Buyback Yield % among Medical Distribution companies is 0.04, based on 37 companies in the industry. Companies in the top quartile (top 25%) have a Buyback Yield % significantly above this median, while those in the bottom quartile fall well below. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Ibnsina Pharma and its competitors. For the Medical Distribution industry, the median Buyback Yield % is 0.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibnsina Pharma's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Fairly Valued. The stock's GF Value™ is E£10.61, compared to a current price of E£11.37 — trading 7.2% above its estimated fair value. The current Buyback Yield % is 0.00. Ibnsina Pharma's overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Buyback Yield % is 0.00 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£11.37 is trading 7.2% above its estimated GF Value™ of E£10.61.
GuruFocus considers Ibnsina Pharma to be Fairly Valued.
Key valuation signals for CAI:ISPH:
Buyback Yield %: 0.00
GF Value™: E£10.61 vs. price of E£11.37 (7.2% above fair value)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
90GF Score
Get the complete analysis for CAI:ISPH
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
